India's No.1 Weekly For The Pharmaceutical Industry
About us || Feedback|| Advertising || Subscribe || Archives / Search 

 

Issue dated - 23rd Dec 2004

Home > Technology Trendz > Story Printer Friendly Page|  Email this page

Medtronic offers insulin pumps in Indian market

EPP News Bureau Mumbai Medtronic offers Model 508 series insulin pumps help insulin-dependent patients improve their blood sugar control. In fact, maintaining near-normal blood sugar levels using predictable, rapid-acting insulin, delivered precisely and on command by an insulin pump can help patients reduce their risk of diabetes-related complications, including blindness, kidney failure, amputation, impotence and heart disease.

An A1c measurement reflects patients’ average blood sugar control over a two-to-three month period. Patients maintaining target A1c levels using Model 508 series insulin pumps can live longer, healthier lives. Clinician and patient acceptance of insulin pump therapy has been very favourable in India. ‘‘There is a growing body of evidence supporting insulin pump therapy for improved glycaemic control,’’ states S K Wangnoo, MD, a leading diabetologist in Delhi and India.

Once patients begin using an insulin pump, 97 per cent remain on pump therapy. Results from a randomised, controlled, crossover trial in five countries throughout Europe recently demonstrated that pump users achieved significantly better overall quality of life compared to those using injection therapy. The pump users had less diabetes-related worry, higher treatment satisfaction and improved flexibility in terms of eating habits, lifestyle and sleep patterns.

Moreover, 100 per cent of the study’s pump users recommended insulin pump therapy, while only 63 percent of the injection users recommended traditional syringe therapy to treat diabetes. In fact, pump therapy is associated with less risk of hypoglycaemia (low blood sugar), which is a common concern among many diabetes patients. Clinical studies have proven that insulin pumps can reduce severe hypoglycaemia by up to 85 percent and mild-to-moderate hypoglycaemia by up to 60 percent, compared to injection therapy.

Patients using Medtronic’s Model 508 series insulin pumps can customise basal insulin delivery using three different basal patterns, each with up to 48 different basal rates. This customisation allows for changing lifestyle needs, such as exercise, sick days and during sleep, a time when fluctuating blood sugar levels cause concern for many patients.

Additional features include a low volume alert, an optional vibrate mode, and a child block feature to restrict programming for children with curious fingers. Model 508 series insulin pumps hold a large 3 ml reservoir and store up to 90 days of data, which can be downloaded to a personal computer to help patients and their physicians review insulin requirements for improved diabetes management. Model 508 and Model 508R insulin pumps share the same pump features. Model 508 insulin pumps are sold with a four-year warranty and include a remote control device for more discreet insulin delivery.

INSIDE PHARMA
IN THE NEWS
EDIT
OPED
CORPORATE
HAPPENINGS
MARKET PLACE
HEALTH NEWS
TECHNOLOGY TRENDZ
CONVERSATION
PRODUCTS
Pharma Research
(Adobe PDF file)
[an error occurred while processing this directive]
ARCHIVES
SUBSCRIBE
CUSTOMER SERVICE
CONTACT US
ADVERTISE
ABOUT US

 Network Sites

  Express Computer

  IT People
  Network Magazine
  Business Traveller
  Hotelier & Caterer
  Travel & Tourism
  Healthcare Mgmt.
  Express Textile
 Group Sites
  ExpressIndia
  Indian Express
  Financial Express
<Top of page>
ABOUT US FEEDBACK ADVERTISE SUBSCRIBE ARCHIVES
 

© Copyright 2001: Indian Express Newspapers (Bombay) Limited (Mumbai, India). All rights reserved throughout the world. This entire site is compiled in Mumbai by the Business Publications Division (BPD) of the Indian Express Newspapers (Bombay) Limited. Site managed by BPD.